16.09.2024 14:20:44

Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season - Quick Facts

(RTTNews) - Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for Children program.

BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

For More Such Health News, visit rttnews.com.

Analysen zu Sanofi S.A.mehr Analysen

24.01.25 Sanofi Neutral JP Morgan Chase & Co.
23.01.25 Sanofi Buy UBS AG
16.01.25 Sanofi Neutral JP Morgan Chase & Co.
07.01.25 Sanofi Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.01.25 Sanofi Outperform Bernstein Research
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Sanofi S.A. (spons. ADRs) 50,50 0,00% Sanofi S.A. (spons. ADRs)
Sanofi S.A. 103,68 3,16% Sanofi S.A.